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Acute liver failure (ALF) can be the consequence of various etiologies, that might
vary between different geographic regions. Most frequent are intoxications with aceta-
minophen, viral hepatitis, or liver damage of unknown origin. ALF occurs when the extent
of hepatocyte death exceeds the regenerative capacity of the liver. The mode of liver cell
death that is predominantly induced in ALF, i.e., apoptosis or necrosis, is still controversial
and presumably determined by the etiology, duration, and magnitude of liver injury. Severe
liver damage involves oxidative stress and depletion of ATP resulting in necrosis. In con-
trast, maintenance of ATP stores is required for the execution of apoptosis. Recent data
suggest that necrosis resulting from severe liver damage is associated with poor outcome
of ALF patients. Discrimination between apoptosis and necrosis might be therefore useful
for the identiﬁcation of ALF patients requiring liver transplantation. Identiﬁcation of the
molecular cell death mechanisms remains an important issue not only for early prediction
of ALF outcome, but also for therapeutic interventions. In view of the pleiotropic func-
tions of critical mediators of cell death and tissue regeneration, a particular challenge will
be to reduce hepatocellular death without inhibiting the regenerative capacity of the liver.
Here, we review the molecular mechanisms of hepatocyte injury and the pathways lead-
ing to apoptosis and necrosis, which might represent potential diagnostic and therapeutic
targets in ALF.
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INTRODUCTION
Acute liver failure (ALF) can occur as a result of various etiolo-
gies including hepatic injury by drugs and poison, viral hepatitis,
ischemia, or other causes. The mechanisms by which liver cells
are destroyed as well as the processes mediating liver regenera-
tion, remain largely unknown. It has become evident that liver cell
death can occur via distinct biochemical pathways and morpho-
logical alterations, including apoptosis, autophagic cell death, and
necrosis. Apoptosis is deﬁned by chromatin condensation, nuclear
fragmentation, cell shrinkage, blebbing of the plasma membrane,
and formation of apoptotic bodies that contain nuclear or cyto-
plasmic material (Kerr et al., 1972; Russell et al., 1972). Autophagic
cell death, on the other hand, is characterized by a massive
accumulation of double-membrane containing vacuoles, called
autophagosomes, that subsequently fuse with lysosomes. Necrotic
cell death is often negatively deﬁned as a form of cell death that
lacks signs of apoptosis or autophagy. Typically, necrotic cells show
cytoplasmic swelling, dilation of organelles, and mechanical rup-
ture of the plasma membrane. Although necrosis has been deemed
to be a mainly passive process, the initiation, and modulation of
necrotic cell death are currently under intense investigation at the
molecular level.
The relative contribution of apoptosis or necrosis to organ dys-
function in ALF remains controversial (Schulze-Osthoff and Ban-
tel, 2011). Necrosis is typically the consequence of acute metabolic
perturbation with ATP depletion, whereas apoptosis represents an
ATP-dependent cell death program. Furthermore, in several cases,
the nature and duration of cellular injury determine if cells die by
apoptosis, necrosis, or othermechanisms.At low doses, a variety of
injurious stimuli often induce apoptosis, but the same stimuli can
result in necrosis at higher doses. Therefore, in many situations
cell death might be not executed as a clear-cut form of cell death,
but as a continuum with intermediate features of both apoptosis
and necrosis. A distinction of different cell death forms is there-
fore not only relevant for semantical reasons, but has important
clinical implications when considering the therapeutic targeting
of cell death processes. Thus, an understanding of the cell death
processes is most important for development of effective interven-
tions to prevent hepatocellular death in acute liver damage (Fischer
and Schulze-Osthoff, 2005).
DEATH RECEPTOR SIGNALING IN ACUTE LIVER FAILURE
Apoptosis represents a programmed form of cell death that is
required for the maintenance of tissue homeostasis by counter-
balancing cell proliferation and eliminating damaged, infected,
or transformed cells. This process is particularly important in
the liver as an organ that is naturally exposed to toxins, drugs,
and viruses. However, excessive apoptosis can result in tissue
destruction and organ failure.
Apoptosis results from a collapse of cellular infrastructure
through internal proteolytic digestion, which leads to cytoskeletal
disintegration, metabolic derangement, and genomic fragmenta-
tion. Members of the caspase family of proteases form the core
engine of apoptosis and are involved in initiation, execution,
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and regulatory phases of the pathway. Caspases are cysteine pro-
teases that cleave substrates after aspartate residues within spe-
ciﬁc peptide recognition sequences. To preclude unwarranted cell
death, caspases are expressed as inactive zymogens consisting of a
prodomain followed by two subunits with the catalytic domain.
Caspases operate in hierarchical cascades that serve to amplify
the apoptotic signal (Los et al., 1999). Based on their structure
and order in cell death pathways, caspases can be divided into
upstream initiators and downstream effectors of apoptosis. Effec-
tor caspases such as caspase-3, -6, and -7 cleave diverse cellular
substrates including structural proteins such as cytokeratin-18 and
many others (Fischer et al., 1998; Leers et al., 1999; Bantel et al.,
2000, 2001a). In contrast, initiator caspases, such as caspase-8, -9,
and -10, exert regulatory roles by activating downstream effector
caspases.
Caspases are activated by two major signaling routes, namely
the extrinsic death receptor and the intrinsic mitochondrial path-
way, that both depend on the formation of large multi-protein
complexes (Schulze-Osthoff et al., 1998; Yoon and Gores, 2002).
Initiator caspase-8 is the key mediator of the extrinsic pathway.
In a simpliﬁed model, binding of death ligands such as TRAIL
or CD95L or tumor necrosis factor (TNF)-α to their respective
death receptors leads to receptor oligomerization. This event then
results in the recruitment of the adapter protein FADDand the ini-
tiator caspase-8 into a death-inducing signaling complex (DISC),
wherein caspase-8 becomes activated by dimerization and auto-
proteolytic cleavage (Figure 1). Subsequently, caspase-8 cleaves
and activates the effector caspase-3, culminating in the demise of
so-called type I cells. In most cells including hepatocytes, however,
only low amounts of initiator caspases are activated at the DISC,
which is insufﬁcient for cell death. In those type II cells, the extrin-
sic receptor pathway must be ampliﬁed by the intrinsic mitochon-
drial apoptotic pathway through the caspase-8-mediated cleavage
of Bid, a pro-apoptotic Bcl-2 family protein, which subsequently
initiates together with the Bcl-2 family members Bak and Bax the
release of mitochondrial pro-apoptotic mediators (Schwerk and
Schulze-Osthoff, 2005). Interestingly, CD95-induced hepatocyte
apoptosis is delayed but not inhibited in Bak/Bax-deﬁcient mice
indicating that hepatocytes can act as type I cells in the absence of
pro-apoptotic Bcl-2 proteins (Hikita et al., 2011).
Inappropriate activation of death receptors might lead to ALF.
This has been impressively demonstrated in mice that died rapidly
FIGURE 1 | Simplified scheme of cell death and survival pathways
involved inALF. Activation ofTNF receptor-1 can mediate NF-κB activation,
apoptosis, or necroptosis. The different outcomes are determined by
distinct TNF receptor-associated signaling complexes. Activation of NF-κB
is mediated byTRAF-2, RIP-1, and other signaling molecules that lead to
activation of IκB kinase and subsequent activation of NF-κB target genes.
FADD and caspase-8 are the essential adapter proteins involved in
apoptosis, which in hepatocytes requires a mitochondrial ampliﬁcation
loop through caspase-8-mediated cleavage of Bid. The subsequent
translocation of Bax and Bak results in mitochondrial outer membrane
permeabilization, cytochrome c release, and effector caspase-3 activation.
Under conditions of impaired apoptosis, TNF receptor-1 can induce
necroptosis, which involves RIP-1 and RIP-3 kinases. Among other effects,
RIP-3 can increase the production of reactive oxygen species (ROS) due to
increased oxidative phosphorylation, resulting in intracellular calcium
overload, mitochondrial membrane permeability transition (MPT),
depletion of ATP, and necrosis. APAP-induced necrosis is essentially
mediated by a toxic metabolite, which depletes glutathione and forms
APAP protein adducts, triggering oxidative stress, compromised
respiratory function, and ATP depletion. Although APAP treatment can
instigate the mitochondrial pathway of apoptosis, high doses of APAP will
ultimately mediate liver cell death by necrosis.
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of liver failure with massive hepatocyte apoptosis when agonis-
tic anti-CD95 antibody was injected (Ogasawara et al., 1993).
Similarly, treatment of mice with TNF-α in combination with a
transcription-blocking agent, such as d-galactosamine (d-GalN)
or actinomycin D, induces lethal hepatitis (Leist et al., 1994, 1995;
Libert et al., 1994). Another well established mouse model of ALF
consists of a combined treatment with d-GalN and lipopolysac-
charide (LPS), which induces TNF-α expression and an inﬂam-
matory response that is predominantly directed toward the liver
(Galanos et al., 1979).
It has been suggested that the toxicity in the murine TNF-α and
anti-CD95 models resembles viral forms of acute hepatic failure in
patients (Keppler et al., 1968; El-Mofty et al., 1975). CD95/CD95L
expression has been shown to be upregulated in viral hepatitis
and to correlate with disease activity and hepatocyte apoptosis
(Hiramatsu et al., 1994; Mita et al., 1994; Pianko et al., 2001;
Lee et al., 2004). We have recently demonstrated that diseased,
e.g., HCV-infected, livers show an upregulation of TRAIL recep-
tors and increased susceptibility toward TRAIL-induced apoptosis
(Volkmann et al., 2007). These data implicate that viral forms of
ALF are associated with death receptor-induced cell death. Recent
data show that the CD95 system is involved in human ALF caused
not only by viral hepatitis but also by Wilson’s disease (Strand
et al., 1998; Rivero et al., 2002). Increased levels of death ligands or
receptors such as CD95L, TNF-α, or TNF receptors (TNF-R) were
found in blood of patients with ALF (Ryo et al., 2000; Streetz et al.,
2000; Tokushige et al., 2000; Nakae et al., 2001; Volkmann et al.,
2008). Particularly, high serum levels of soluble death receptor
CD95 have also been found in drug-induced ALF (Tagami et al.,
2003; Rutherford et al., 2007).
Silencing of CD95 or caspase-8 protected mice from ALF or
fulminant hepatitis induced by agonistic CD95 antibody or con-
canavalin A, respectively (Song et al., 2003; Zender et al., 2003).
However, CD95 and caspase-8 also promotes liver regeneration
by inducing differentiation of stellate cells and possibly of other
non-parenchymal liver cells (Desbarats and Newell, 2000; Canbay
et al., 2003; Ben Moshe et al., 2007). Additionally, TNF-α plays
a pivotal role in liver regeneration by activation of transcription
factors such as NF-κB, which induces the transcription of a huge
number of cytokines and growth-promoting target genes (Wul-
laert et al., 2007). The activation of NF-κB by TNF-α is mediated
by distinct adapter proteins that are recruited to TNF-R-1 upon
ligand binding (Figure 1). Whether increased levels of circulating
death receptors or ligands in human ALF mirror apoptotic cell
death or liver regeneration and whether death receptor-induced
cell death depends on special ALF etiologies remains unknown.
ROLE OF MITOCHONDRIAL DAMAGE IN ACUTE LIVER
FAILURE
In contrast to viral infection, drug-induced liver injury is mainly
associated with signaling pathways triggered by mitochondrial
damage (Chan et al., 2005). In the intrinsic pathway, apoptosis
is mediated by translocation of pro-apoptotic Bcl-2 molecules,
such as Bax and Bak, from the cytosol to mitochondria to form
pores in the outermitochondrialmembrane (Los et al., 1999). This
process is followed by the mitochondrial release of cytochrome c
andother pro-apoptotic factors. Cytochrome c normally functions
in electron transport processes of the respiratory chain to generate
ATP. In the cytosol of apoptotic cells, however, it serves as a cofac-
tor for the adapter protein Apaf-1. Upon binding of cytochrome c
and dATP, Apaf-1 oligomerizes, and recruits the initiator caspase-
9 to trigger the formation of the apoptosome. Thus, similar to
the DISC, the apoptosome is a high-molecular weight complex
that serves as a caspase activation platform. Once assembled in
the apoptosome, caspase-9 becomes activated and subsequently
triggers the caspase cascade (Schulze-Osthoff et al., 1998). As
mentioned above, there is also considerable crosstalk between
the extrinsic and intrinsic pathways. For example, during death
receptor-mediated apoptosis caspase-8 can proteolytically activate
the Bcl-2 protein Bid, which facilitates cytochrome c release and
ampliﬁes the apoptotic signal following death receptor activation.
In contrast to apoptosis, necrosis is mediated by opening of the
mitochondrial membrane permeability transition (MPT) pore,
which triggers the collapse of the membrane potential and ces-
sation of ATP formation. The resulting mitochondrial swelling
leads to the rupture of the outer mitochondrial membrane with
the release of intermembrane proteins and subsequent nuclear
DNA fragmentation. Other prominent features include massive
energy depletion, formation of reactive oxygen species (ROS),
and activation of non-apoptotic proteases. Furthermore, during
necrosis a strong increase of intracellular calcium is observed.
The elevated calcium levels in the cytosol trigger mitochondrial
calcium overload, leading to depolarization of the inner mito-
chondrial membrane and a shut-down of ATP production. While
depletion of ATP impedes the function of membrane channels,
increased calcium activates calcium-dependent proteases, such
as calpains. Calcium ﬂuxes, ATP depletion, and oxidative stress
involve complex and interactive feedback loops,which self-amplify
and potentiate each other leading to exaggerated cell death. The
relative amount of ATP might be an important factor that deter-
mines whether hepatocytes die by apoptosis or necrosis (Ferrari
et al., 1998;Hinson et al., 2010). Another important distinguishing
feature of apoptotic versus necrotic cell death relates to inﬂamma-
tion. When the necrotic cell ruptures, an inﬂammatory response
follows due to the release of intracellular contents. In contrast,
inﬂammation is not typical of apoptosis, because phagocytic cells
rapidly engulf apoptotic cells and thereby prevent the release of
noxious intracellular compounds.
CELL DEATH MECHANISMS INVOLVED IN
ACETAMINOPHEN-INDUCED ACUTE LIVER FAILURE
Acetaminophen (paracetamol, N -acetyl-p-aminophenol; APAP)
overdose represents one of the most common causes of ALF in
developed countries (Larson et al., 2005). APAP-induced hepa-
totoxicity is due to the formation of the toxic metabolite N -
acetyl-p-benzoquinone imine by the cytochrome P450 system,
which causes glutathione depletion, oxidative stress, alterations
of calcium homeostasis, resulting in MPT, loss of mitochondr-
ial membrane potential, and ATP depletion (Hinson et al., 2010).
Although necrosis has been thought to be the predominant mode
of cell death in APAP-induced liver injury, conﬂicting in vitro and
animal data have emerged suggesting a potential role of apoptosis
in acetaminophen-induced hepatotoxicity (El-Hassan et al., 2003;
Kon et al., 2004). Mice treated with a toxic dose of acetaminophen
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showed 40% apoptotic and 60% necrotic hepatocytes (Ray et al.,
1996). It was demonstrated thatmicewith defectiveCD95 receptor
(lpr mice) or CD95 ligand (gld mice) were partially protected from
APAP-induced liver injury (Liu et al., 2004). Moreover, increased
circulating levels of CD95 have been found in humans with APAP
intoxication (Tagami et al., 2003).
It has been recently suggested that APAP hepatotoxicity is
caused by the mitochondrial apoptosis pathway and facilitated by
chemokine (C-X-C motif) receptor 2 (CXCR2) signaling. In this
study caspase inhibition prevented DNA fragmentation, although
the authors did not investigate whether caspase inhibition was
also associated with cell survival (Hu and Colletti, 2010; Schulze-
Osthoff and Bantel, 2011). In contrast, in another study no caspase
activation was observed and, accordingly, caspase inhibition did
not protect from liver injury in APAP-treated mice (Jaeschke et al.,
2006). Further data from animal models revealed also no evi-
dence that apoptotic cell death contributes to APAP-induced liver
injury. For instance, following the application of an APAP over-
dose in mice, less than 1% of the parenchymal cells revealed an
apoptotic morphology (Gujral et al., 2002). Another study in mice
showed that knockdown of the CD95 receptor protected against
300mg/kg APAP overdose but not against 700mg/kg overdose
(Zhang et al., 2000), indicating that the mode of cell death might
at least partially depend on the APAP dose. Indeed, several stud-
ies demonstrated that APAP induces mitochondrial dysfunction
with ATP depletion which even interrupts initial CD95-induced
mitochondrial signaling pathways (Lawson et al., 1999; Knight and
Jaeschke, 2002). On the other hand, subliminal CD95 activation
can also increase APAP-induced liver injury (Tinel et al., 2004),
indicating that death receptor signaling might inﬂuence the extent
of APAP-induced necrotic liver injury.
Conﬂicting data exist also about the role of TNF-α in APAP-
induced liver injury. Increased TNF-α expression in liver and
circulating TNF-α levels have been observed after APAP poison-
ing (Blazka et al., 1995, 1996). However, the role of TNF-α in
APAP-inducednecrosis remains controversial, as TNF-α inhibitors
exerted either protection or no effect (Blazka et al., 1995; Simpson
et al., 2000). In addition, TNF-α knockout mice showed similar
sensitivity to acetaminophen compared to wildtype mice (Boess
et al., 1998). It has been recently shown that inhibition of c-jun
N-terminal kinase (JNK), a member of the mitogen-activated pro-
tein kinase family, reduced paracetamol-induced toxicity in mice
by inhibiting hepatic TNF-α production (Henderson et al., 2007).
Furthermore, APAP-induced JNK activation has been linked to
activation of the pro-apoptotic Bcl-2 protein Bim. In line, APAP-
induced necrotic liver injury was shown to be reduced in Bim
knockout mice (Badmann et al., 2011). However, neither JNK1
nor JNK2 knockdown did protect mice from APAP-induced liver
toxicity, raising concerns about a major role of JNK in APAP-
induced liver injury (Gunawan et al., 2006; Henderson et al., 2007;
Bourdi et al., 2008). Altogether, although apoptotic alterations can
occur, profound energy depletion, and mitochondrial failure pre-
sumably divert cell death to necrosis as the principal mode of
APAP-induced liver toxicity.
Autophagy represents another process that might inﬂuence
the outcome of APAP-induced liver toxicity. Autophagy is a
catabolic mechanism by which long-lived proteins and organelles
are recycled in order to maintain energy and protein synthesis. It
is characterized by the appearance of numerous cytosolic vacuole-
like structures, called autophagosomes, which encapsulate cytoso-
lic materials and fuse with lysosomes. Although the role of the
autophagy in protection during nutrient starvation is accepted, its
function in programmed cell death remains controversial. Under
normal physiological conditions autophagyoccurs at lowbasal lev-
els, contributing to the turnover of cytoplasmic components and
promoting cell survival during stress conditions. Excess autophagy,
on the other hand, leads to autophagic cell death. Interestingly, it
has been recently demonstrated that APAP induces autophagy in
mouse liver and primary human hepatocytes and that activation
of autophagy protects against APAP-induced hepatotoxicity (Ni
et al., 2012). In this study it was suggested that the induction of
oxidative stress might play an important role in APAP-induced
autophagy. Moreover, it was shown that pharmacological inhibi-
tion of autophagy increased APAP-induced liver injury. Clearly,
more work is needed to elucidate the role of autophagy in APAP-
induced hepatotoxicity and the complex crosstalk with other cell
death pathways.
CELL DEATH BIOMARKERS FOR MONITORING ACUTE LIVER
FAILURE
In addition to measuring death ligands, several other cell death
biomarkers have been proposed for monitoring the clinical out-
come of ALF and other liver diseases (Volkmann et al., 2006;
Rutherford et al., 2007; Bechmann et al., 2008; Joka et al., 2012).
Caspases cleave the intermediate ﬁlament protein cytokeratin
(CK)-18 into speciﬁc fragments that are released into circulat-
ing blood and can be detected by the M30 ELISA (Bantel et al.,
2001b, 2004; Seidel et al., 2005). Moreover, when this assay is
combined with a second ELISA that detects the total release of
caspase-cleaved and uncleaved CK-18 (M65 ELISA), even differ-
ent forms of cell death, such as necrosis and apoptosis, can be
discriminated. Using these serological assays, it has been recently
demonstrated that the predictive sensitivity of total CK-18 for
lethal outcome was comparable to the model for end-stage liver
disease (MELD) score at time of admission of ALF patients (Bech-
mann et al., 2010). Moreover, modiﬁcation of the MELD score by
substitution of bilirubin for total CK-18 signiﬁcantly increased the
prediction of ALF outcome.
Interestingly, we have demonstrated that ALF patients display
considerable caspase activity and high levels of caspase-cleaved
CK-18 in the serum, which was unexpectedly higher in spon-
taneous survivors than in patients that required transplantation
or died (Volkmann et al., 2008). Nevertheless, despite a weaker
activation of caspases, liver biopsies of patients without sponta-
neous recovery revealed extensive TUNEL reactivity,which detects
both apoptotic and necrotic cell death. Moreover, sera from those
patients contained increased levels of total CK-18, but reduced
levels of its caspase-generated fragments as compared to patients
with spontaneous recovery. These ﬁndings therefore indicate that
necrosis but not apoptosis is the predominant cell death in
those critically ill ALF patients, whereas in ALF patients with
spontaneous recovery apoptotic cell death predominates. In con-
trast, in another study, detection of caspase-cleaved CK-18 could
not adequately predict ALF outcome (Rutherford et al., 2007).
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However, unlike in our study in which APAP-induced ALF only
played a minor role, in this study a relevant number of patients
with APAP-induced ALF was included. As mentioned above, in
those patients necrotic cell death might predominate irrespective
of the outcome. In line with this observation, patients with APAP-
induced ALF showed higher levels of total CK-18 compared to
caspase-cleaved CK-18 levels (Bechmann et al., 2008; Volkmann
et al., 2008; Craig et al., 2011; Bantel and Schulze-Osthoff, 2012).
Caspase activation might also play a role in liver regeneration
and this might explain our observation of higher caspase activity
in spontaneous survivors. Caspases can cleave different cytokine
precursors to generate active cytokines and thus create an environ-
ment that could be essential for liver regeneration. Experiments in
mice showed that caspase activation is associated with chemokine
production and inﬂammation in the liver, whereas caspase-3 inhi-
bition strongly reduced activity of pro-inﬂammatory transcription
factors and chemokines (Faouzi et al., 2001). A role of caspases in
liver regeneration is best exempliﬁed by a recent report showing
that a hepatocyte-speciﬁc knockout of caspase-8 attenuates hepa-
tocyte proliferation after partial hepatectomy (Ben Moshe et al.,
2007).
In addition to cell death biomarkers, circulating levels of nucle-
osomes and high-mobility group box 1 (HMBG1) protein, both of
which are released during hepatocyte death, have been shown to be
elevated in patients with ALF (Roth et al., 2009; Craig et al., 2011).
However, those biomarkers were not able to predict ALF outcome,
and no signiﬁcant differences in HMBG1 or nucleosome levels
between paracetamol- and non-paracetamol-induced liver injury
were found (Craig et al., 2011). One explanation for the lacking
correlation of those biomarkers with ALF outcome might be that
the release of HMBG1 and nucleosomes are not strictly related
to necrotic cell death, but also occur during apoptosis (Bell et al.,
2006; Jaeschke et al., 2012). Certainly, further larger cohort studies
are required to evaluate the predictive value of cell death markers
in patients with paracetamol- or non-paracetamol-induced ALF.
POSSIBLE THERAPEUTIC STRATEGIES FOR CELL DEATH
INHIBITION IN ACUTE LIVER FAILURE
An admixture of necrosis and apoptosis occurs in ALF and might
therefore open up novel strategies for therapeutic intervention
(Fischer and Schulze-Osthoff, 2005). More extreme injury leads
to necrotic killing, whereas milder injury may result in apoptosis.
Whether inhibition of apoptosis using available pharmacologi-
cal caspase inhibitors can indeed prevent liver cell death or will
just simply shift the mode of cell death to necrosis, remains to
be shown (Los et al., 2002). As caspases not only play a role in
apoptosis but also in processes of liver regeneration, the possi-
bility of adverse effects should not be ignored when consider-
ing the therapeutic use of caspase inhibitors in ALF treatment.
Death receptor-blocking agents, such as CD95-Fc or TRAIL-R-
Fc proteins, might be promising candidates in virus-induced ALF
(Bantel and Schulze-Osthoff, 2003). MicroRNAs (miRNAs) are
non-coding RNAs which have been implicated in the posttran-
scriptional regulation of various cellular pathways. It was recently
demonstrated that overexpression of miRNA-221 delays CD95-
induced fulminant liver failure in mice (Sharma et al., 2011). Thus,
miRNAs involved in cell death signaling pathways might serve as
potential therapeutic targets in ALF.
Due to the pleiotropic effects of TNF-α, inhibitors of this
cytokine might not only inﬂuence liver cell death but also immune
response and liver regeneration. Treatment of APAP intoxicated
mice with anti-TNF-α partially prevented hepatotoxicity (Blazka
et al., 1995). Other studies showed no alterations of APAP toxi-
city in mice treated either with anti-TNF-α antibody or soluble
TNF receptor (Simpson et al., 2000). Whether the observed dis-
crepancy is due to the variant experimental conditions, such as
different mouse strains, remains to be elucidated (Jaeschke et al.,
2012). There is increasing evidence suggesting that TNF-α triggers
cell death not only by apoptosis, but also by a necrosis-like process,
which has been recently called necroptosis (Schulze-Osthoff et al.,
1994; Vandenabeele et al., 2010). Whereas TNF-α-induced apop-
tosis involves caspase-8, TNF-α-induced necroptosis is essentially
mediated by the kinases RIP-1 andRIP-3 that are recruited toTNF-
R1 (Figure 1). Interestingly, speciﬁc inhibitors of RIP-1, called
necrostatins, have been recently designed as novel cytoprotective
agents that might be a promising tool to positively inﬂuence ALF
outcome, at least in conditions in which death receptor-mediated
necrosis predominates.
Therapeutic targets to improve APAP-induced ALF outcome
might be JNK or other members of the mitogen-activated pro-
tein kinase family, such as p38. JNK inhibition by SP600125, a
small-molecule reversible ATP-competitive inhibitor, or by D-
JNKII, a peptide inhibitor that inhibits the interaction of JNK with
substrates, markedly reduced mortality in murine paracetamol-
induced hepatotoxicity, with a signiﬁcant reduction of hepatic
apoptosis and necrosis (Bennett et al., 2001; Borsello et al.,
2003; Henderson et al., 2007). Since glutathione depletion and
subsequent oxidative stress formation are key pathogenic mech-
anisms of APAP-induced hepatocyte death, application of N -
acetylcysteine, a pro-drug for glutathione synthesis, which has
been shown to reduce APAP-induced liver necrosis, is the current
standard therapy in APAP-induced ALF (Corcoran et al., 1985;
Saito et al., 2010). In addition, other drugs with anti-oxidant
effects might improve ALF outcome. In this respect, applica-
tion of cyclooxygenase inhibitors exerted protective effects in an
experimental ALF mouse model with decreased oxidative stress
formation and marked reduction of hepatic necrosis (Chang
et al., 2011; Liong et al., 2012). A novel therapeutic target in
ALF that connects the immune system with cell death might be
cyclophilin A. This intracellular protein exerts pro-inﬂammatory
and hepatotoxic activity when released from necrotic liver cells in
APAP-induced liver injury. Conversely, inhibition of cyclophilin
reduced inﬂammatory response tonecrotic liver (Dear et al., 2011).
Thus, targeting of cyclophilin might represent an opportunity
for a novel therapeutic approach in acetaminophen poisoning.
As mentioned above, pharmacological inhibition of autophagy
exacerbated APAP-induced liver toxicity. Vice versa, induction
of autophagy by rapamycin was shown to inhibit APAP-induced
hepatotoxicity (Ni et al., 2012). Thus, autophagy induction might
be a further strategy to improveALF outcome inAPAP intoxicated
patients.
Taken together, there are many promising therapeutic
approaches for inhibition of APAP- and non-APAP-induced ALF.
However, it should be kept in mind that most of the described
targets exert a pleiotropic role and might interfere not only with
cell death but also with survival pathways.
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